Bayer’s All-or-Nothing Summer: A Supreme Court Ruling and a $7.25bn Settlement Duel

Two legal milestones are converging on Bayer within weeks, and the market is holding its breath. By the end of this June, the US Supreme Court is expected to rule on the “Durnell” case — a landmark decision on whether federal regulatory approval of glyphosate preempts state-level warning-label lawsuits. Shortly after, on July 9, 2026, a federal court in Missouri will decide whether to approve the company’s $7.25bn settlement covering future Roundup claims. Together, these dates will determine whether Bayer finally exits the legal quagmire that has hung over its stock for years.

The stock is stuck in a technical no-man’s-land that mirrors this uncertainty. After a 39% rally over the past twelve months, the shares have gone sideways since January. They currently trade at €37.08, down 1.15% on the day, having briefly spiked nearly 5% on Wednesday when a federal judge in St. Louis rejected an attempt to move the settlement proceedings to California. The 200-day moving average at €36.17 provides floor support, while the 50-day average at €37.85 caps any upward momentum. The relative strength index sits at 52 — squarely neutral territory, with an annualized volatility of 33% suggesting violent swings once a fundamental catalyst arrives.

Behind the price action, CEO Bill Anderson is pressing ahead with an operational overhaul. His “Dynamic Shared Ownership” model is stripping away layers of bureaucracy and pushing decision-making closer to the front lines. Early fruits are visible: the Preceon Smart Corn System, a short-stalked maize variety offering greater resilience against extreme weather, is gaining traction in the agriculture division. In pharmaceuticals, the FDA has approved Elinzanetant (branded Lynkuet) for menopause symptoms, while Nubeqa and Kerendia continue to add pipeline potential. The market capitalisation of roughly €37bn arguably still fails to reflect the leaner cost base.

Should investors sell immediately? Or is it worth buying Bayer?

European lawmakers have also handed Bayer a tailwind. The EU Parliament recently voted to loosen regulations on new genomic techniques, allowing minor gene edits to be marketed without special labels and keeping patent protection intact. The rules are expected to take effect in mid-2028, opening up fresh growth avenues for the crop-science business.

Yet these operational and regulatory positives are being overshadowed by the judicial calendar. The Supreme Court’s decision on preemption is widely seen as an all-or-nothing moment: a win would sever the heaviest liability from Bayer’s balance sheet, while a loss would keep the company locked in years of costly settlements and reserves. The Missouri court’s subsequent ruling on the $7.25bn settlement will then seal the near-term legal framework.

Institutional signals are mixed. Goldman Sachs has trimmed its voting rights stake to 4.89%, while Jefferies maintains a hold rating with a €40 price target, citing residual uncertainties until the glyphosate saga is fully concluded. The 52-week high of €49.93 still looms 25% above current levels, suggesting real upside if the legal clouds lift. For now, a sustained break above €40 would be the clearest bullish signal, while a failure to hold the 200-day line could reopen the path towards the 52-week low of €25.09 — not the base case, but a reminder of the stakes.